Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Bioequivalence of IHL-42X in Healthy Volunteers
NCT05857384Phase 1Completed
- Sponsor
- Incannex Healthcare
- Start
- Sep 2023
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of IHL-42X in obstructive sleep apnea (OSA) (4 arms), sponsored by Incannex Healthcare. Primary endpoints: Bioavailability of IHL-42X at 28 days, Bioequivalence of IHL-42X at 28 days and 5 more. Started Sep 2023; status: completed.
02
Drugs
IHL-42X
03
Conditions
obstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT05857384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05857384.